Əsas səhifə

Çap

Əks əlaqə

İnfo
Positive pressure airway support for cardiogenic pulmonary oedema

Mündəricat

Positive pressure airway support for cardiogenic pulmonary oedema

Sübutlu məlumatların xülasələri
06.08.2013 • Sonuncu dəyişiklik 06.08.2013
Editors

CPAP reduces mortality and the need for subsequent mechanical ventilation in patients with acute cardiogenic pulmonary oedema as compared to standard care.

A Cochrane review included 32 studies with a total of 2 916 subjects. Non-invasive positive pressure ventilation (NPPV), including continuous positive airway pressure (CPAP) and bilevel NPPV, was compared with standard medical care. NPPV (CPAP or bilevel NPPV) significantly reduced hospital mortality and endotracheal intubation with numbers needed to treat of 14 and 8, respectively (table ). There was no difference in hospital length of stay with NPPV, however, intensive care unit stay was reduced by 1 day. No significant increases in the incidence of acute myocardial infarction with NPPV during or after its application were observed. Fewer adverse events, in particular progressive respiratory distress and neurological failure (coma), were observed with NPPV use compared with standard medical care.

Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema compared with standard medical care.
Outcome Relative effect (95% CI) Assumed risk – Usual care Corresponding risk - NPPV *Participants (studies)
* NPPV = non-invasive positive pressure ventilation (CPAP and bilevel NPPV)
Hospital mortality RR 0.66 (0.48 to 0.89) 204 per 1000 135 per 1000 (98 to 182) 1 107 (20 studies)
Endotracheal intubation rate RR 0.52 (0.36 to 0.75) 249 per 1000 130 per 1000 (90 to 187) 1 261 (22 studies)
Acute myocardial infarction (during intervention) RR 1.24 (0.79 to 1.95) 153 per 1000 190 per 1000 (121 to 299) 461 (8 studies)
Acute myocardial infarction (after intervention) RR 0.7 (0.11 to 4.26) 26 per 1000 18 per 1000 (3 to 111) 154 (4 studies)
Intolerance to allocated treatment RR 0.47 (0.29 to 0.77) 234 per 1000 110 per 1000 (68 to 180) 1 848 (13 studies)
Hospital length of stay The mean hospital length of stay in the intervention groups was 0.8 days lower (2.1 lower to 0.51 higher) 542 (10 studies)
Intensive care unit length of stay The mean intensive care unit length of stay in the intervention groups was 0.89 days lower (1.33 to 0.45 lower) 222 (6 studies)

There was lower hospital mortality (table ) and endotracheal intubation rate (table ) in CPAP-treated patients compared with standard care. Bilevel NPPV tended to lower hospital mortality and endotracheal intubation rate compared with standard care but the results were not statistically significant. No differences were found when CPAP and bilevel NPPV were compared directly.

Hospital mortality
Comparison Relative effect (95% CI) Participants (studies)
NPPV = non-invasive positive pressure ventilation
CPAP versus standard care RR 0.60 (0.39 to 0.94) 699 (13 studies)
Bilevel NPPV versus standard care RR 0.65 (0.39 to 1.09) 506 (11 studies)
CPAP versus bilevel NPPV RR 1.10 (0.61 to 1.97) 694 (12 studies)
Endotracheal intubation rate
Comparison Relative effect (95% CI) Participants (studies)
NPPV = non-invasive positive pressure ventilation
CPAP versus standard care RR 0.47 (0.33 to 0.67) 825 (14 studies)
Bilevel NPPV versus standard care RR 0.55 (0.26 to 1.17) 536 (12 studies)
CPAP versus bilevel NPPV RR 1.04 (0.55 to 1.97) 721 (13 studies)

Comment: The authors state that CPAP can be considered the first option in selection of NPPV due to more robust evidence for its effectiveness and safety and lower costs compared with bilevel NPPV.

Ədəbiyyat

  1. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013;(5):CD005351.